Using advanced bioinformatics
Next-generation sequencing (NGS) and polymerase chain reaction (PCR), have enabled the medical field to discover biomarkers and subsequent cancer therapies targeting biopathways. The introduction of liquid biopsy has helped streamline the collection process and reduce the time to develop a personalized therapy based upon the tumor’(s) or patient’s molecular fingerprint.
CIRCULOGENE provides oncologists with best-in-class cancer assessment for patients resulting in a complete and accurate molecular profile for treatment determination, patient responsiveness, and cancer progression monitoring.
CIRCULOGENE is powered by the patented Linear In Situ Amplification (LISA) methodology which results in twice the yield of cfDNA and preserves the fragile cfRNA, as compared to other methods. Our use of NGS and PCR instrumentation combines the breadth of cfDNA menu as well as the accuracy for cfRNA detection. These two technological advancements are the basis for CIRCULOGENE’s best-in-class menu offerings including: TumorClear, ImmunoClear, and MSI Complete.